<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360334</url>
  </required_header>
  <id_info>
    <org_study_id>H8O-BP-GWBG</org_study_id>
    <nct_id>NCT00360334</nct_id>
  </id_info>
  <brief_title>A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients</brief_title>
  <official_title>An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral
      antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic
      control, as measured by hemoglobin A1c, with minimum weight gain, in patients with
      uncontrolled type 2 diabetes on OADs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Composite endpoint evaluating effect of treatment on glycemic control and weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Who Achieved HbA1c ≤ 7.4% and Weight Gain ≤ 0.5kg</measure>
    <time_frame>26 weeks</time_frame>
    <description>Composite endpoint evaluating effect of treatment on glycemic control and weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Glucose</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in fasting serum glucose from baseline (week 0) to endpoint (week 26)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving HbA1c ≤ 7.4%</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of patients achieving specified HbA1c target at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving HbA1c &lt; 7%</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of patients achieving specified HbA1c target at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving HbA1c &lt; 6.5%</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of patients achieving specified HbA1c target at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 7 Point Self Monitored Blood Glucose Profile</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from baseline to endpoint in self monitored blood glucose levels measured at 7 time points during the day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in BMI from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Change in waist circumference from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist-to-hip Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in waist-to-hip ratio from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in body weight from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Percent change in baseline body weight at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving 5% Weight Loss</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of patients who lost at least 5% of baseline body weight at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving 10% Weight Loss</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of patients who lost at least 10% of baseline body weight at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in systolic blood pressure from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in diastolic blood pressure from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Total Cholesterol (TC)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in TC from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Density Lipoprotein (HDL) Cholesterol</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in HDL cholesterol from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TC to HDL Cholesterol Ratio</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in TC to HDL cholesterol ratio from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Triglycerides</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in fasting serum triglycerides from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in LDL cholesterol from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein-B</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in apolipoprotein-B from baseline to endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycemic Episodes</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of total patients in each arm experiencing hypoglycemia at any point in the 26 week study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nocturnal Hypoglycemic Episodes</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of total patients in each arm experiencing nocturnal hypoglycemia at any point in the 26 week study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe Hypoglycemic Episodes</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent of total patients in each arm experiencing severe hypoglycemia at any point during the 26 week study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Rate Per 30 Days</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of hypoglycemic episodes per patient adjusted per 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Hypoglycemic Rate Per 30 Days</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of nocturnal hypoglycemic episodes per patient adjusted per 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypoglycemic Rate Per 30 Days</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of severe hypoglycemic episodes per patient adjusted per 30 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>subcutaneous injection, 5mcg or 10mcg, twice a day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>subcutaneous injection, titrated to target blood glucose level, once a day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes

          -  Currently being treated with the following: Dual or triple oral therapy - on a stable
             combination and dose for at least 3 months.

          -  HbA1c between 7.5% and 10.0%.

          -  BMI &gt;27.

        Exclusion Criteria:

          -  Receive chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
             (excluding topical and inhaled preparations) or have received such therapy within 2
             weeks immediately prior to study.

          -  Have participated in an interventional medical, surgical, or pharmaceutical study (a
             study in which a medical or surgical treatment was given) within 30 days prior to
             entry into the study.

          -  Treatment with the following medications: *Insulin as outpatient therapy within last 3
             months; *Meglitinides, or acarbose within the last 3 months; *Regular use of any drugs
             that directly affect gastrointestinal motility; *Any previous (study) therapy with
             exenatide or glucagon-like peptide-1 (GLP-1) analogue; *Anti-obesity agent use within
             the last 3 months.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Silva de Lima, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blackburn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haywards Heath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>High Wycombe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Livingstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middlesborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oldham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochdale</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torquay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wakefield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009 Dec;11(12):1153-62. doi: 10.1111/j.1463-1326.2009.01154.x.</citation>
    <PMID>19930005</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2006</study_first_submitted>
  <study_first_submitted_qc>August 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2006</study_first_posted>
  <results_first_submitted>April 14, 2009</results_first_submitted>
  <results_first_submitted_qc>April 14, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2009</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>exenatide</keyword>
  <keyword>insulin glargine</keyword>
  <keyword>Lilly</keyword>
  <keyword>Amylin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 35 study centers in the United Kingdom. Recruitment occurred from June 2006 to October 2007.</recruitment_details>
      <pre_assignment_details>One patient assigned to the Insulin Glargine group withdrew from the study prior to receiving study drug. This patient is not included in the analysis set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide</title>
          <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
        </group>
        <group group_id="P2">
          <title>Insulin Glargine</title>
          <description>dosing based on treat to target protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="118">FAS = received ≥ 1 dose of study drug</participants>
                <participants group_id="P2" count="116">FAS = received ≥ 1 dose of study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry criterion not met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exenatide</title>
          <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
        </group>
        <group group_id="B2">
          <title>Insulin Glargine</title>
          <description>dosing based on treat to target protocol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="234"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="10.2"/>
                    <measurement group_id="B2" value="56.2" spread="7.9"/>
                    <measurement group_id="B3" value="56.5" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Types of oral antidiabetic medication combinations administered at baseline</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>metformin and sulfonylurea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>metformin and thiazolidinedione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sulfonylurea and thiazolidinedione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>metformin, sulfonylurea, and thiazolidinedione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline apolipoprotein-B</title>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.84" spread="0.24"/>
                    <measurement group_id="B2" value="0.88" spread="0.24"/>
                    <measurement group_id="B3" value="0.86" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline fasting serum glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.84" spread="2.23"/>
                    <measurement group_id="B2" value="10.12" spread="2.22"/>
                    <measurement group_id="B3" value="10.48" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline fasting serum total cholesterol (TC)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.45" spread="1.05"/>
                    <measurement group_id="B2" value="4.63" spread="1.20"/>
                    <measurement group_id="B3" value="4.54" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline fasting serum triglycerides</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.94" spread="1.01"/>
                    <measurement group_id="B2" value="2.31" spread="2.24"/>
                    <measurement group_id="B3" value="2.13" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline high density lipoprotein (HDL) cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.14" spread="0.24"/>
                    <measurement group_id="B2" value="1.15" spread="0.29"/>
                    <measurement group_id="B3" value="1.15" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline low density lipoprotein (LDL) cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.38" spread="0.82"/>
                    <measurement group_id="B2" value="2.49" spread="1.02"/>
                    <measurement group_id="B3" value="2.43" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline total cholesterol to high density lipoprotein cholesterol ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.00" spread="1.10"/>
                    <measurement group_id="B2" value="4.29" spread="2.15"/>
                    <measurement group_id="B3" value="4.15" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)</title>
        <description>Composite endpoint evaluating effect of treatment on glycemic control and weight</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set; The last post-baseline measurement set of both non-missing HbA1c and weight was used as endpoint value. Patients who did not have a baseline weight measurement and/or missing post-baseline measurements for HbA1c and/or weight were included in the analysis as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)</title>
          <description>Composite endpoint evaluating effect of treatment on glycemic control and weight</description>
          <population>Full Analysis Set; The last post-baseline measurement set of both non-missing HbA1c and weight was used as endpoint value. Patients who did not have a baseline weight measurement and/or missing post-baseline measurements for HbA1c and/or weight were included in the analysis as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4"/>
                    <measurement group_id="O2" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the primary outcome divided by the odds of a patient in the insulin glargine arm achieving the primary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.62</ci_lower_limit>
            <ci_upper_limit>8.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Who Achieved HbA1c ≤ 7.4% and Weight Gain ≤ 0.5kg</title>
        <description>Composite endpoint evaluating effect of treatment on glycemic control and weight</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set; The last post-baseline measurement set of both non-missing HbA1c and weight was used as endpoint value. Patients who did not have a baseline weight measurement and/or missing post-baseline measurements for HbA1c and/or weight were included in the analysis as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Who Achieved HbA1c ≤ 7.4% and Weight Gain ≤ 0.5kg</title>
          <description>Composite endpoint evaluating effect of treatment on glycemic control and weight</description>
          <population>Full Analysis Set; The last post-baseline measurement set of both non-missing HbA1c and weight was used as endpoint value. Patients who did not have a baseline weight measurement and/or missing post-baseline measurements for HbA1c and/or weight were included in the analysis as non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.11</ci_lower_limit>
            <ci_upper_limit>10.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Glucose</title>
        <description>Change in fasting serum glucose from baseline (week 0) to endpoint (week 26)</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Glucose</title>
          <description>Change in fasting serum glucose from baseline (week 0) to endpoint (week 26)</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="0.25"/>
                    <measurement group_id="O2" value="-3.61" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Achieving HbA1c ≤ 7.4%</title>
        <description>Percent of patients achieving specified HbA1c target at endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward. Patients with no post-baseline HbA1c measurement are regarded as non-responders in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Achieving HbA1c ≤ 7.4%</title>
          <description>Percent of patients achieving specified HbA1c target at endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward. Patients with no post-baseline HbA1c measurement are regarded as non-responders in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                    <measurement group_id="O2" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.280</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Achieving HbA1c &lt; 7%</title>
        <description>Percent of patients achieving specified HbA1c target at endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward. Patients with no post-baseline HbA1c measurement are regarded as non-responders in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Achieving HbA1c &lt; 7%</title>
          <description>Percent of patients achieving specified HbA1c target at endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward. Patients with no post-baseline HbA1c measurement are regarded as non-responders in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7"/>
                    <measurement group_id="O2" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Achieving HbA1c &lt; 6.5%</title>
        <description>Percent of patients achieving specified HbA1c target at endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward. Patients with no post-baseline HbA1c measurement are regarded as non-responders in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Achieving HbA1c &lt; 6.5%</title>
          <description>Percent of patients achieving specified HbA1c target at endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward. Patients with no post-baseline HbA1c measurement are regarded as non-responders in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.363</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>3.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 7 Point Self Monitored Blood Glucose Profile</title>
        <description>Change from baseline to endpoint in self monitored blood glucose levels measured at 7 time points during the day</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 7 Point Self Monitored Blood Glucose Profile</title>
          <description>Change from baseline to endpoint in self monitored blood glucose levels measured at 7 time points during the day</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-breakfast: Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.98" spread="2.11"/>
                    <measurement group_id="O2" value="9.88" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-breakfast: Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="2.14"/>
                    <measurement group_id="O2" value="-3.99" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs after breakfast: Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.53" spread="3.07"/>
                    <measurement group_id="O2" value="13.33" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs after breakfast: Change at endpt (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.09" spread="3.52"/>
                    <measurement group_id="O2" value="-3.95" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-lunch: Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="3.24"/>
                    <measurement group_id="O2" value="9.54" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-lunch: Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="3.11"/>
                    <measurement group_id="O2" value="-2.59" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs after lunch: Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.07" spread="3.27"/>
                    <measurement group_id="O2" value="11.15" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs after lunch: Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="3.30"/>
                    <measurement group_id="O2" value="-2.48" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dinner: Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="2.97"/>
                    <measurement group_id="O2" value="9.37" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dinner: Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="2.89"/>
                    <measurement group_id="O2" value="-1.46" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs after dinner: Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.59" spread="3.28"/>
                    <measurement group_id="O2" value="11.80" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs after dinner: Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.59" spread="3.30"/>
                    <measurement group_id="O2" value="-2.06" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime: Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.63" spread="3.23"/>
                    <measurement group_id="O2" value="11.24" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime: Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.56" spread="3.19"/>
                    <measurement group_id="O2" value="-2.20" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index (BMI)</title>
        <description>Change in BMI from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index (BMI)</title>
          <description>Change in BMI from baseline to endpoint</description>
          <population>Full Analysis Set</population>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.49" spread="0.49"/>
                    <measurement group_id="O2" value="33.71" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.11"/>
                    <measurement group_id="O2" value="1.01" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model Repeated Measures</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <description>Change in waist circumference from baseline to endpoint</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>Change in waist circumference from baseline to endpoint</description>
          <population>Full Analysis Set</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.07" spread="1.30"/>
                    <measurement group_id="O2" value="110.64" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="0.54"/>
                    <measurement group_id="O2" value="1.97" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model Repeated Measures</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist-to-hip Ratio</title>
        <description>Change in waist-to-hip ratio from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist-to-hip Ratio</title>
          <description>Change in waist-to-hip ratio from baseline to endpoint</description>
          <population>Full Analysis Set</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.01"/>
                    <measurement group_id="O2" value="0.98" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.00"/>
                    <measurement group_id="O2" value="0.01" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model Repeated Measures</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Change in body weight from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Change in body weight from baseline to endpoint</description>
          <population>Full Analysis Set</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.19" spread="1.68"/>
                    <measurement group_id="O2" value="97.93" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="0.31"/>
                    <measurement group_id="O2" value="2.98" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model Repeated Measures</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight</title>
        <description>Percent change in baseline body weight at endpoint</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight</title>
          <description>Percent change in baseline body weight at endpoint</description>
          <population>Full Analysis Set</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="0.3"/>
                    <measurement group_id="O2" value="3.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Repeated Measures</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Achieving 5% Weight Loss</title>
        <description>Percent of patients who lost at least 5% of baseline body weight at endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward. For change in weight, patients should have a baseline and at least one post-baseline weight measurement. Otherwise, these patients are included as non-responders in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Achieving 5% Weight Loss</title>
          <description>Percent of patients who lost at least 5% of baseline body weight at endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward. For change in weight, patients should have a baseline and at least one post-baseline weight measurement. Otherwise, these patients are included as non-responders in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>27.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.70</ci_lower_limit>
            <ci_upper_limit>210.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Achieving 10% Weight Loss</title>
        <description>Percent of patients who lost at least 10% of baseline body weight at endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward. For change in weight, patients should have a baseline and at least one post-baseline weight measurement. Otherwise, these patients are included as non-responders in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Achieving 10% Weight Loss</title>
          <description>Percent of patients who lost at least 10% of baseline body weight at endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward. For change in weight, patients should have a baseline and at least one post-baseline weight measurement. Otherwise, these patients are included as non-responders in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>Change in systolic blood pressure from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>Change in systolic blood pressure from baseline to endpoint</description>
          <population>Full Analysis Set</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.0" spread="1.5"/>
                    <measurement group_id="O2" value="134.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="1.2"/>
                    <measurement group_id="O2" value="0.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mixed Model Repeated Measures</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <description>Change in diastolic blood pressure from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <description>Change in diastolic blood pressure from baseline to endpoint</description>
          <population>Full Analysis Set</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="0.8"/>
                    <measurement group_id="O2" value="79.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at endpoint (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.7"/>
                    <measurement group_id="O2" value="0.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <method>Mixed Model Repeated Measures</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Total Cholesterol (TC)</title>
        <description>Change in TC from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Total Cholesterol (TC)</title>
          <description>Change in TC from baseline to endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.07"/>
                    <measurement group_id="O2" value="-0.21" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High Density Lipoprotein (HDL) Cholesterol</title>
        <description>Change in HDL cholesterol from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High Density Lipoprotein (HDL) Cholesterol</title>
          <description>Change in HDL cholesterol from baseline to endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="0.02" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.471</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TC to HDL Cholesterol Ratio</title>
        <description>Change in TC to HDL cholesterol ratio from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TC to HDL Cholesterol Ratio</title>
          <description>Change in TC to HDL cholesterol ratio from baseline to endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.10"/>
                    <measurement group_id="O2" value="-0.34" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Triglycerides</title>
        <description>Change in fasting serum triglycerides from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Triglycerides</title>
          <description>Change in fasting serum triglycerides from baseline to endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.08"/>
                    <measurement group_id="O2" value="-0.38" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.650</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low Density Lipoprotein (LDL) Cholesterol</title>
        <description>Change in LDL cholesterol from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Density Lipoprotein (LDL) Cholesterol</title>
          <description>Change in LDL cholesterol from baseline to endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.06"/>
                    <measurement group_id="O2" value="-0.07" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apolipoprotein-B</title>
        <description>Change in apolipoprotein-B from baseline to endpoint</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set, Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apolipoprotein-B</title>
          <description>Change in apolipoprotein-B from baseline to endpoint</description>
          <population>Full Analysis Set, Last Observation Carried Forward</population>
          <units>g/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.02"/>
                    <measurement group_id="O2" value="-0.08" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.667</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycemic Episodes</title>
        <description>Percent of total patients in each arm experiencing hypoglycemia at any point in the 26 week study</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycemic Episodes</title>
          <description>Percent of total patients in each arm experiencing hypoglycemia at any point in the 26 week study</description>
          <population>Full Analysis Set</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.675</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.401</ci_lower_limit>
            <ci_upper_limit>1.136</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Nocturnal Hypoglycemic Episodes</title>
        <description>Percent of total patients in each arm experiencing nocturnal hypoglycemia at any point in the 26 week study</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nocturnal Hypoglycemic Episodes</title>
          <description>Percent of total patients in each arm experiencing nocturnal hypoglycemia at any point in the 26 week study</description>
          <population>Full Analysis Set</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.317</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.159</ci_lower_limit>
            <ci_upper_limit>0.630</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Severe Hypoglycemic Episodes</title>
        <description>Percent of total patients in each arm experiencing severe hypoglycemia at any point during the 26 week study</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Severe Hypoglycemic Episodes</title>
          <description>Percent of total patients in each arm experiencing severe hypoglycemia at any point during the 26 week study</description>
          <population>Full Analysis Set</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) = odds of a patient in the exenatide arm achieving the secondary outcome divided by the odds of a patient in the insulin glargine arm achieving the secondary outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.716</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.797</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.235</ci_lower_limit>
            <ci_upper_limit>2.705</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Rate Per 30 Days</title>
        <description>Number of hypoglycemic episodes per patient adjusted per 30 days</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Rate Per 30 Days</title>
          <description>Number of hypoglycemic episodes per patient adjusted per 30 days</description>
          <population>Full Analysis Set</population>
          <units>Number of episodes per 30 days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069" lower_limit="0.000" upper_limit="0.495"/>
                    <measurement group_id="O2" value="0.164" lower_limit="0.000" upper_limit="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.113</p_value>
            <method>ANCOVA on ranks</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal Hypoglycemic Rate Per 30 Days</title>
        <description>Number of nocturnal hypoglycemic episodes per patient adjusted per 30 days</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Hypoglycemic Rate Per 30 Days</title>
          <description>Number of nocturnal hypoglycemic episodes per patient adjusted per 30 days</description>
          <population>Full Analysis Set</population>
          <units>Number of episodes per 30 days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000" upper_limit="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA on ranks</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Hypoglycemic Rate Per 30 Days</title>
        <description>Number of severe hypoglycemic episodes per patient adjusted per 30 days</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>dosing based on treat to target protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Hypoglycemic Rate Per 30 Days</title>
          <description>Number of severe hypoglycemic episodes per patient adjusted per 30 days</description>
          <population>Full Analysis Set</population>
          <units>Number of episodes per 30 days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.000" upper_limit="0.989"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000" upper_limit="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.740</p_value>
            <method>ANCOVA on ranks</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Exenatide</title>
          <description>5mcg twice daily for 4 weeks, followed by 10mcg twice daily for 22 weeks</description>
        </group>
        <group group_id="E2">
          <title>Insulin Glargine</title>
          <description>dosing based on treat to target protocol</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5"/>
                <counts group_id="E2" subjects_affected="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Wrong drug administered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105"/>
                <counts group_id="E2" subjects_affected="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Bowel sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Ohman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

